tradmap

IOVA Iovance Biotherapeutics, Inc.

$3.91 -0.51%

Healthcare · Biological Products, (No Diagnostic Substances)

Iovance Biotherapeutics, Inc. (IOVA) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $1.7 billion. Shares last traded at $3.91, 30.6% below their 52-week high. Over the past year the stock is up 95.5%. Net profit margin is -148.4%, below the peer median of 6.3%. Revenue grew 60.6% year over year.

Market Cap
$1.7B
Shares Out
446.5M
EPS (TTM)
$-2.27
P/E Ratio
P/S Ratio
6.63
P/B Ratio
2.42
Dividend / Share
Dividend Yield
52-Week High
$5.63
52-Week Low
$1.67
Volume
465,019
Avg Vol (3m)
648,580.508

Performance

1W
-1.26%
1M
+12.68%
3M
+1.30%
6M
+74.94%
YTD
+55.16%
1Y
+95.50%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
50.07
SMA (50)
$3.79
SMA (200)
$2.97
Price vs SMA50
+3.30%
Price vs SMA200
+31.70%
ATR (14)
$0.31

Financials

Revenue
$264M
Net Income
$-391M
Gross Margin
Operating Margin
-153.1%
Net Margin
-148.4%
Return on Equity
-54.2%
Return on Assets
-42.2%
Current Ratio
3.60
Debt / Equity
0.28
Revenue Growth (YoY)
+60.6%

Latest reported annual period ending 2025-12-31 · SEC EDGAR/XBRL.

Recent earnings

PeriodEPS (diluted)Reported
Q1 2026 $-0.19 2026-05-07
FY 2025 $-1.09 2026-02-24
Q2 2025 $-0.69 2025-08-07
Q1 2026 $-0.36 2026-05-07
FY 2025 $-1.28 2026-02-24
Q3 2024 $-1.03 2024-11-07

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

IOVA vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap.

P/S vs peers
6.63 / 5.21 med
+27% premium
Net margin vs peers
-148.4% / 6.3% med
below median
1–14 of 14
AMGNAmgen$182.1B23.624.9621.0%-1.27%
GILDGilead Sciences$153.5B18.045.2128.9%-1.46%
RVMDRevolution Medicines, Inc.$34.6B-30.62+3.14%
BIIBBiogen$29.0B22.442.9313.1%-1.15%
MRNAModerna$25.4B-8.99+3.22%
NBIXNeurocrine Biosciences Inc$15.9B33.245.5616.7%-0.48%
EXELExelixis, Inc.$13.1B16.685.6233.7%-1.04%
KRYSKrystal Biotech, Inc.$10.2B50.0226.3352.6%+1.68%
TECHBio-Techne$9.1B123.617.446.0%+5.36%
HALOHalozyme Therapeutics, Inc.$8.1B25.675.8222.7%-0.03%
IBRXImmunitybio, Inc.$7.7B-21.87+5.01%
RGENRepligen Corp$7.4B152.2710.086.6%-1.20%
KYMRKymera Therapeutics, Inc.$7.4B23.88+0.44%
PCVXVaxcyte, Inc.$7.4B-9688.00+1.57%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.